Home2019-05-04T00:45:33-05:00

DCISionRT, the Only DCIS Test to Predict Radiation Therapy Benefit

Hear why DCISionRT is great news for patients

For Doctors

The Test

For Patients

preludedx dcisionrt logo

The DCIS Test That Enables Personalized Treatment

dcisionrt personalized treatment vertical

DCISionRT enables physicians to deliver precision medicine to DCIS patients

Results are shown are for the 196 patients treated with conserving surgery treated patients with clear margins in a multisite study. Total recurrence risks shown are adjusted for year of diagnosis. This was demonstrated in a multisite study of 474 patients1.

1 Bremer T, Whitworth P, Patel R, et al. . A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res . 2018; doi:10.1158/1078-0432.CCR-18-0842.